(Total Views: 517)
Posted On: 02/25/2021 8:38:21 PM
Post# of 153868
Hasn't the time expired in which Dr Nader P. must reveal to share holders, any relevant negative information from the s/c trial, that could effect the share price?
And thus, we can assume we did achieve Stat Significance for PE?
Or is that ambiguous? Like if the Primary Endpoint was not met, yet the FDA....
1) is considering issuing a partial or limited EUA, say to certain sub-groups
2) is considering issuing a EUA based upon Statistical Significance for several Secondary Endpoints and Clinical Significance for Primary Endpoint.
And thus, we can assume we did achieve Stat Significance for PE?
Or is that ambiguous? Like if the Primary Endpoint was not met, yet the FDA....
1) is considering issuing a partial or limited EUA, say to certain sub-groups
2) is considering issuing a EUA based upon Statistical Significance for several Secondary Endpoints and Clinical Significance for Primary Endpoint.
(1)
(0)
